United States VEGF Antibody Market was valued at USD 1.5 Billion in 2022 and is projected to reach USD 2.9 Billion by 2030, growing at a CAGR of 8.6% from 2024 to 2030.
The VEGF Antibody Market is gaining significant momentum as the demand for targeted therapies in the treatment of cancer, age-related macular degeneration (AMD), and other vascular diseases increases. Vascular Endothelial Growth Factor (VEGF) antibodies have proven to be effective in inhibiting angiogenesis, a process that plays a crucial role in the development of various diseases. This market has become an essential area of interest for both pharmaceutical companies and healthcare providers.
In the US, the demand for VEGF antibodies is driven by the growing number of patients with cancer, particularly those suffering from solid tumors, and the increasing prevalence of ophthalmic disorders like AMD. The effectiveness of these antibodies in preventing the formation of new blood vessels, which tumors and abnormal tissues rely on for growth, has made them a staple in oncology and ophthalmology treatments. According to recent trends, these therapies are projected to continue expanding, providing lucrative opportunities for the industry.
The key types of VEGF antibodies in the market include monoclonal antibodies like Bevacizumab (Avastin), which has been a dominant player in the treatment of colorectal cancer and lung cancer. Other newer candidates and biosimilars are also emerging, contributing to market diversification. These antibody therapies are not only improving patient outcomes but are also becoming increasingly affordable due to biosimilar options being introduced in the market.
Industries are also pushing for more personalized treatments, leading to increased investments in the development of VEGF antibody-based therapies. The biotech sector, in particular, is exploring how these antibodies can be integrated with other treatment modalities such as immunotherapy or chemotherapy to improve the efficacy and overall survival rates of patients. As the healthcare sector adapts to these new advancements, the demand for highly specialized VEGF antibodies is expected to continue rising.
The requirement for VEGF antibodies in industries is primarily driven by healthcare providers' focus on improving treatment outcomes and reducing side effects. In the next decade, VEGF antibodies are set to play a critical role in reshaping the landscape of cancer and ophthalmology treatments in the US, with industry stakeholders actively working towards optimizing their clinical applications.
Get an In-Depth Research Analysis of the US VEGF Antibody Market Size And Forecast [2025-2032]
Â
Thermo Fisher
MilliporeSigma
Santa Cruz Biotechnology
Abcam
R&D Systems
Novus Biologicals
Abnova
ImmunoStar
OriGene
LifeSpan Biosciences
Sino Biological
Bio-Rad
BioLegend
Rockland Immunochemicals
Agrisera
Boster
ProMab
Creative Biomart
Enzo Life Sciences
Bon Opus Biosciences
Absolute Antibody
US Biological
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US VEGF Antibody Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US VEGF Antibody Market
Cancer
Age-related Macular Degeneration (AMD)
Diabetic Retinopathy
Other retinal diseases
Monoclonal Antibodies
Bispecific Antibodies
Polyclonal Antibodies
Conjugated Antibodies
Therapeutic Applications
Diagnostic Applications
Research Applications
Pharmaceutical Companies
Biotechnology Firms
Research Laboratories
Hospitals and Clinics
Direct Sales
Distributors
Online Sales
Retail Pharmacies
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ VEGF Antibody Market Research Analysis
1. Introduction of the US VEGF Antibody Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US VEGF Antibody Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US VEGF Antibody Market, By Type
6. US VEGF Antibody Market, By Application
7. US VEGF Antibody Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US VEGF Antibody Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/